...Hi, everyone. I'm Gary Nachman, a senior biopharma analyst at BMO, and we're really excited to have Ionis management participating with us in BMO's Growth and ESG Conference. We have Eugene Schneider, Head of Clinical Development; and Roslyn Patterson, VP of Marketing and Communications. Ionis has a great platform in RNA-targeted antisense technology with a very robust portfolio across cardiovascular disease and neurology. And the company recently announced a deal with Metagenomi, expanding its capabilities into gene editing. So a lot of exciting programs in the pipeline that we'll be able to cover, and it's great to have you guys here to discuss that with us. So thank you for being here. Eugene Schneider ...